Clinical Trial Update: The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AVM0703 for lymphoid malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies

Drugs mentioned

• AVM0703

Snippet

Sponsor: AVM Biotechnology Inc | Conditions: Lymphoid Malignancies | Phase 1, Phase 2 | Status: RECRUITING